Imatinib selectively inhibits the proliferation and induces apoptosis in BCR-ABL–positive cell lines as well as fresh leukemic cells from patients with Philadelphia chromosome-positive CML and Philadelphia chromosome-positive acute lymphoblastic leukemia [7,8]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.